pipeline

pipeline
Saviximab®(Anti-SARS-CoV-2) Nanobody

SARS-CoV-2

Optimization Pre-clinical ADMET/CMC Ph Ⅰ Ph Ⅱ
IV

Shaperon has successfully developed Saviximab®, a single domain neutralizing antibody for SARS-CoV-2.

Saviximab® shows excellent therapeutic effects in the hamster model infected with the SARS-CoV-2 virus by suppressing the proliferation of SARS-CoV-2 virus in the lung tissue and reducing inflammation and swelling.